Chemomab Therapeutics Ltd. (CMMB) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
KIRYAT ATIDIM, BUILDING 7 TEL AVIV, 6158002 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 13,519 | 15,186 | 5,392 | 17,575 | |||
| Cash and cash equivalent | 13,519 | 15,186 | 5,392 | 17,575 | |||
| Restricted cash and investments | 77 | ||||||
| Receivables | 408 | ||||||
| Prepaid expense | 1,307 | 1,348 | |||||
| Deposits current assets | 26,374 | 45,975 | |||||
| Other undisclosed current assets | 459 | 179 | 724 | 228 | |||
| Total current assets: | 41,736 | 62,688 | 6,116 | 18,211 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 227 | 345 | 1,199 | ||||
| Property, plant and equipment | 367 | 357 | 12 | 158 | |||
| Prepaid expense | 733 | 908 | 57 | ||||
| Restricted cash and investments | 55 | ||||||
| Other noncurrent assets | 51 | ||||||
| Other undisclosed noncurrent assets | 130 | ||||||
| Total noncurrent assets: | 1,327 | 1,665 | 63 | 1,544 | |||
| TOTAL ASSETS: | 43,063 | 64,353 | 6,179 | 19,755 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 5,066 | 2,544 | 678 | 875 | |||
| Employee-related liabilities | ✕ | ✕ | 653 | ||||
| Accounts payable | 1,688 | 1,336 | 678 | 875 | |||
| Accrued liabilities | 3,378 | 555 | |||||
| Debt | 391 | ||||||
| Postemployment benefits liability | 262 | ||||||
| Other liabilities | 1,729 | 2,296 | |||||
| Other undisclosed current liabilities | 1,683 | 106 | 179 | 297 | |||
| Total current liabilities: | 6,749 | 2,650 | 2,586 | 4,121 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation: | 237 | 16 | 725 | ||||
| Liabilities, other than long-term debt | 91 | ||||||
| Operating lease, liability | 91 | 237 | 16 | 725 | |||
| Other undisclosed noncurrent liabilities | (237) | (16) | |||||
| Total noncurrent liabilities: | 91 | 237 | 16 | 725 | |||
| Total liabilities: | 6,840 | 2,887 | 2,602 | 4,846 | |||
| Equity | |||||||
| Equity, attributable to parent | 36,223 | 61,466 | 3,577 | 14,909 | |||
| Treasury stock, value | (1,218) | ||||||
| Additional paid in capital | 101,260 | 97,639 | 119,745 | 119,468 | |||
| Accumulated other comprehensive income | 872 | 872 | |||||
| Accumulated deficit | (63,819) | (36,173) | (117,040) | (105,431) | |||
| Total equity: | 36,223 | 61,466 | 3,577 | 14,909 | |||
| TOTAL LIABILITIES AND EQUITY: | 43,063 | 64,353 | 6,179 | 19,755 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|
| Revenues (Net Investment Income) | 20 | 393 | ||||
| Cost of revenue (Cost of Product and Service Sold) | (5,142) | (3,310) | ||||
| Gross profit: | (5,142) | (3,310) | 20 | 393 | ||
| Operating expenses | (28,533) | (12,367) | (11,712) | (22,898) | ||
| Other undisclosed operating loss | ||||||
| Operating loss: | (33,675) | (15,677) | (11,692) | (22,505) | ||
| Nonoperating income | 353 | |||||
| Interest and debt expense | (6) | (9) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (33,322) | (15,677) | (11,698) | (22,514) | ||
| Other undisclosed income from continuing operations before income taxes | 5,142 | 28,155 | 23,307 | 49,638 | ||
| Income (loss) from continuing operations before income taxes: | (28,180) | 12,478 | 11,609 | 27,124 | ||
| Income tax benefit | 534 | |||||
| Income (loss) from continuing operations: | (27,646) | 12,478 | 11,609 | 27,124 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | 12,478 | 11,609 | 27,124 | ||
| Other undisclosed net loss | (24,956) | (23,218) | (54,248) | |||
| Net loss available to common stockholders, diluted: | (27,646) | (12,478) | (11,609) | (27,124) | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|
| Net loss: | (27,646) | (12,478) | (11,609) | (27,124) | ||
| Comprehensive loss: | (27,646) | (12,478) | (11,609) | (27,124) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 54,248 | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (27,646) | (12,478) | (11,609) | 27,124 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.